Soleno Therapeutics, Inc. Common Stock
SLNOSoleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and neglected diseases. The company's primary focus has been on treatments for neurological and metabolic disorders, aiming to address unmet medical needs through innovative drug development.
Company News
Soleno Therapeutics (SLNO) stock plunged 28% on November 5, 2025, after the company revealed disappointing launch metrics for VYKAT XR, including lower prescription starts and increased discontinuations due to adverse events. This contradicted the company's September 2025 statements that the launch had 'exceeded expectations.' Short seller Scorpi...
Law firm Bragar Eagel & Squire is investigating potential securities violations at three companies: Soleno Therapeutics following a report questioning its product's safety and pricing, AVITA Medical due to significant claim payment backlogs affecting product utilization, and Coty following unexpected losses and disappointing guidance attributed t...
Pomerantz LLP is investigating potential securities fraud claims against Soleno Therapeutics following a short seller report questioning the safety and pricing of its product Vykat XR. The company disclosed an 8% discontinuation rate due to adverse effects and acknowledged disruption to its product launch. Soleno's stock fell 7.41% after the init...
Rhythm Pharmaceuticals reported promising early Phase 2 trial results for setmelanotide in treating Prader-Willi syndrome, with potential therapeutic benefits in reducing BMI and extreme hunger. The company plans to advance to a Phase 3 trial and has initiated a new trial arm for a MC4R agonist.
Soleno Therapeutics achieved its first profitable quarter with $66 million in revenue, attracting a significant $86.7 million investment from Connecticut-based fund Braidwell, which acquired 1.3 million shares in the biotechnology company.
